MX2022006410A - Uso de masitinib para el tratamiento del asma eosinofilica. - Google Patents
Uso de masitinib para el tratamiento del asma eosinofilica.Info
- Publication number
- MX2022006410A MX2022006410A MX2022006410A MX2022006410A MX2022006410A MX 2022006410 A MX2022006410 A MX 2022006410A MX 2022006410 A MX2022006410 A MX 2022006410A MX 2022006410 A MX2022006410 A MX 2022006410A MX 2022006410 A MX2022006410 A MX 2022006410A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- masitinib
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 3
- 208000006673 asthma Diseases 0.000 title abstract 3
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004655 masitinib Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000003979 eosinophil Anatomy 0.000 abstract 2
- 238000004820 blood count Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation By Low-Temperature Treatments (AREA)
- Percussion Or Vibration Massage (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
La presente invención se refiere a un derivado de 2-aminoariltiazol o una sal o solvato farmacéuticamente aceptable del mismo, en particular masitinib o una sal o solvato farmacéuticamente aceptable del mismo, para su uso en el tratamiento del asma en un sujeto que lo necesite, en donde el sujeto tiene un nivel elevado de eosinófilos. En particular, la presente invención se refiere a un derivado de 2-aminoariltiazol o una sal o solvato farmacéuticamente aceptable del mismo, en particular masitinib o una sal o solvato farmacéuticamente aceptable del mismo, para su uso en el tratamiento del asma en un sujeto con un conteo sanguíneo de eosinófilos en la línea basal que varía desde 150 células/µl hasta 300 células/µl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942377P | 2019-12-02 | 2019-12-02 | |
| EP19306550.5A EP3831384A1 (en) | 2019-12-02 | 2019-12-02 | Use of masitinib for the treatment of eosinophilic asthma |
| PCT/EP2020/084251 WO2021110737A1 (en) | 2019-12-02 | 2020-12-02 | Use of masitinib for the treatment of eosinophilic asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006410A true MX2022006410A (es) | 2022-07-27 |
Family
ID=68917852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006410A MX2022006410A (es) | 2019-12-02 | 2020-12-02 | Uso de masitinib para el tratamiento del asma eosinofilica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230023935A1 (es) |
| EP (2) | EP3831384A1 (es) |
| JP (1) | JP2023503723A (es) |
| KR (1) | KR20220113968A (es) |
| CN (1) | CN115038446A (es) |
| AU (1) | AU2020396190A1 (es) |
| BR (1) | BR112022010524A2 (es) |
| CA (1) | CA3162956A1 (es) |
| IL (1) | IL293205A (es) |
| MX (1) | MX2022006410A (es) |
| WO (1) | WO2021110737A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1525200T3 (da) | 2002-08-02 | 2007-12-03 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling |
| NZ578944A (en) | 2007-02-13 | 2011-03-31 | Ab Science | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS |
| US9078894B2 (en) * | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
| WO2014043442A1 (en) * | 2012-09-14 | 2014-03-20 | Children's Medical Center Corporation | Inhibition of viral infection-triggered asthma with c-kit inhibitor |
-
2019
- 2019-12-02 EP EP19306550.5A patent/EP3831384A1/en not_active Withdrawn
-
2020
- 2020-12-02 AU AU2020396190A patent/AU2020396190A1/en active Pending
- 2020-12-02 CA CA3162956A patent/CA3162956A1/en active Pending
- 2020-12-02 KR KR1020227021484A patent/KR20220113968A/ko unknown
- 2020-12-02 JP JP2022558358A patent/JP2023503723A/ja active Pending
- 2020-12-02 EP EP20816176.0A patent/EP4069230A1/en active Pending
- 2020-12-02 BR BR112022010524A patent/BR112022010524A2/pt not_active Application Discontinuation
- 2020-12-02 US US17/779,722 patent/US20230023935A1/en active Pending
- 2020-12-02 IL IL293205A patent/IL293205A/en unknown
- 2020-12-02 MX MX2022006410A patent/MX2022006410A/es unknown
- 2020-12-02 CN CN202080095286.XA patent/CN115038446A/zh active Pending
- 2020-12-02 WO PCT/EP2020/084251 patent/WO2021110737A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3162956A1 (en) | 2021-06-10 |
| CN115038446A (zh) | 2022-09-09 |
| IL293205A (en) | 2022-07-01 |
| AU2020396190A1 (en) | 2022-06-09 |
| US20230023935A1 (en) | 2023-01-26 |
| JP2023503723A (ja) | 2023-01-31 |
| EP4069230A1 (en) | 2022-10-12 |
| EP3831384A1 (en) | 2021-06-09 |
| BR112022010524A2 (pt) | 2022-08-16 |
| KR20220113968A (ko) | 2022-08-17 |
| WO2021110737A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| PH12016500538A1 (en) | Inhibitors of kras g12c | |
| JO3805B1 (ar) | مثبطات كراس جي12سي | |
| MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| WO2011127070A3 (en) | IRE-1α INHIBITORS | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
| JP2009545620A5 (es) | ||
| MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
| MX2023010063A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| MX2022006410A (es) | Uso de masitinib para el tratamiento del asma eosinofilica. | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| MX2022006045A (es) | Metodos de administracion de voxelotor. | |
| PH12021550572A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| WO2016144704A3 (en) | Heterocyclic autotaxin inhibitor compounds | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| WO2009153434A8 (fr) | Analogues synthetiques des phosphatidyl-myo-inositol mannosides pourvus d'une activite inhibitrice de la reponse inflammatoire. |